Drugs / Fuzaparib
last change Mar 2026 re-read 2 minutes ago

Fuzaparib

Developed for
hormone receptor-positive breast cancer
Investigated by
Xijing Hospital

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07162051 Mar 2023 → Feb 2026 hormone receptor-positive breast cancer Xijing Hospital Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Fuzaparib ClinicalTrials.gov intervention name — accepted as the source's own label NCT07162051